It has recently been reported that a combination of a TGFβ inhibitor and cisplatinum in ovarian cancer cell lines had a stronger anti-proliferative effect than the additive effects of each treatment alone, and promoted tumor regression in established parental and resistant ovarian cancer xenograft models [55]. This evidence concerns the gene TGFB1 and neoplasm.